-
Circulating extracellular vesicle isomiR signatures predict therapy response in patients with multiple myeloma
Gómez-Martín, C., Drees, E. E. E., van Eijndhoven, M. A. J., Groenewegen, N. J., Wang, S., Verkuijlen, S. A. W. M., van Weering, J. R. T., Aparicio-Puerta, E., Bosch, L., Frerichs, K. A., Verkleij, C. P. M., Kersten, M. J., Zijlstra, J. M., de Jong, D., Groothuis-Oudshoorn, C. G. M., Hackenberg, M., de Rooij, J. R., van de Donk, N. W. C. J. & Pegtel, D. M., 21 Oct 2025, In: Cell Rep. Med.. 6, 10, 102358.Research output: Contribution to journal › Article › Academic › peer-review
-
Immune signatures in older patients with newly diagnosed multiple myeloma are associated with survival outcomes of first-line therapy irrespective of frailty levels
Bruins, W. S. C., Smits, F., Duetz, C., Nasserinejad, K., Groen, K., Korst, C. L. B. M., de Jonge, A. V., Rentenaar, R., Hageman, T., Cosovic, M., Eken, M., Twickler, I., Homan-Weert, P. M., Verkleij, C. P. M., Frerichs, K., Levin, M.-D., van der Spek, E., Nijhof, I. S., van Kampen, R. & van de Donk, N. W. C. J. & 2 others, , 1 Oct 2025, In: HemaSphere. 9, 10, e70210.Research output: Contribution to journal › Article › Academic › peer-review
-
The bone marrow NK-cell profile predicts MRD negativity in patients with multiple myeloma treated with daratumumab-based therapy
Korst, C. L. B. M., Tahri, S., Duetz, C., Bruins, W. S. C., de Jonge, A. V., de Jong, M. E., Fokkema, C., Smits, F., Groen, K., Verkleij, C. P. M., Frerichs, K. A., Papazian, N., van Duin, M., van Beek, G., Hoogenboezem, R., Baardemans, T., Dal Collo, G., Stoetman, E. C. G., Cosovic, M. & Twickler, I. & 15 others, , 19 Jun 2025, In: Blood. 145, 25, p. 3007-3014 8 p.Research output: Contribution to journal › Article › Academic › peer-review
- All publications
